2015-06-05 18:30:05 UTC

NASH and Obesity

Clinical Snapshots

About

This AGA Clinical Snapshot is an executive summary of Dr. Diehl's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.

Takeaways

1. Understand the factors that influence non-alcoholic fatty liver disease’s (NAFLD) heterogeneous prognosis and the utility of current diagnostic approaches for determining this.

2. Appreciate controversies regarding which NAFLD patients to treat, as well as the impact of available treatments on NAFLD prognostic factors.

3. Summarize new developments in microbiome/gut-liver axis research that might improve future diagnosis and treatment of NAFLD.

About the Instructors

Anna Mae Diehl, MD, Duke University Medical Center

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

NAFLD is a Common Disease with Heterogeneous Outcomes

Non-alcoholic fatty liver disease (NAFLD) is strongly associated with obesity and the metabolic syndrome. Like obesity and the metabolic syndrome, NAFLD has become highly prevalent. Population based studies suggest that at least 25 percent of American adults have NAFLD. There are two main types of NAFLD …

More on Non-Alcoholic Steatohepatitis (NASH)

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

What is the Best Management Strategy for Patients With NAFLD?

Aug. 8, 2017

It’s essential for physicians to consider patients with non-alcoholic fatty liver disease in a holistic manner. Read more in the AGA Journals blog.

Talking to Patients With NAFLD

July 27, 2017

Five steps to help you approach patients that have non-alcoholic fatty liver disease (NAFLD).